NASDAQ:AGENAgenus Stock Price, Forecast & News

Agenus' stock was trading at $2.72 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AGEN shares have increased by 5.9% and is now trading at $2.88. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Agenus.

Agenus is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Agenus.

Agenus Inc (NASDAQ:AGEN) released its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.33) by $0.02. The biotechnology company earned $15.13 million during the quarter, compared to analyst estimates of $12.35 million. View Agenus' earnings history.

1 analysts have issued 1 year target prices for Agenus' stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate Agenus' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 108.3% from the stock's current price. View analysts' price targets for Agenus.

Press coverage about AGEN stock has been trending extremely negative recently, InfoTrie reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Agenus earned a coverage optimism score of -4.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutAgenus.

Agenus saw a increase in short interest in April. As of April 15th, there was short interest totaling 15,210,000 shares, an increase of 8.7% from the March 31st total of 13,990,000 shares. Based on an average daily volume of 2,400,000 shares, the days-to-cover ratio is currently 6.3 days. Approximately 11.7% of the company's shares are sold short. View Agenus' Current Options Chain.

Some companies that are related to Agenus include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Agenus investors own include Rosetta Genomics (ROSG), Exelixis (EXEL), REDHILL BIOPHAR/S (RDHL), Merrimack Pharmaceuticals (MACK), Opko Health (OPK), Gilead Sciences (GILD), Novavax (NVAX), Energy Transfer LP Unit (ET), Sorrento Therapeutics (SRNE) and Inovio Pharmaceuticals (INO).

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

Agenus' stock is owned by many different retail and institutional investors. Top institutional shareholders include Cormorant Asset Management LP (7.27%), BlackRock Inc. (6.13%), Oracle Investment Management Inc. (3.20%), State Street Corp (2.31%), Geode Capital Management LLC (0.93%) and Wells Fargo & Company MN (0.67%). View institutional ownership trends for Agenus.

AGEN stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Morgan Stanley, Squarepoint Ops LLC, Connor Clark & Lunn Investment Management Ltd., BlackRock Inc., State Street Corp, UBS Group AG, and Alps Advisors Inc.. View insider buying and selling activity for Agenus.

AGEN stock was bought by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Oracle Investment Management Inc., Two Sigma Advisers LP, Cadence Capital Management LLC, Russell Investments Group Ltd., Nuveen Asset Management LLC, Wells Fargo & Company MN, and Trellus Management Company LLC. View insider buying and selling activity for Agenus.

Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AGEN stock can currently be purchased for approximately $2.88.

Agenus has a market capitalization of $482.07 million and generates $150.05 million in revenue each year. The biotechnology company earns $-107,660,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Agenus employs 294 workers across the globe.

The official website for Agenus is agenusbio.com.

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]